| 排名 | 分析师 | 机构 | 行业 | 年度收益率 | 6个月收益率 | 3个月收益率 | 正收益比例 | 成分股数量 | 历史最大跌幅 | 更新日期 |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 阳景 | 浦银国际证券 | 医药生物 | 70.34% | 64.36% | 36.71% | 100.00% | 3 | 0.00% | 2025-07-29 |
| 2 | 胡晨曦 | 长城国瑞证券 | 医药生物 | 70.31% | 65.35% | 37.01% | 12.50% | 6 | -27.10% | 2025-06-17 |
| 3 | 刘浩 | 华创证券 | 医药生物 | 69.94% | 50.94% | 50.73% | 29.41% | 2 | -47.33% | 2025-06-03 |
| 4 | 唐寅灏 | 中信证券 | 医药生物 | 69.82% | 48.25% | 20.69% | 85.71% | 13 | -8.47% | 2025-09-19 |
| 5 | 刘浩 | 华创证券 | 医药生物 | 69.42% | 72.47% | 19.58% | 29.41% | 2 | -47.33% | 2025-07-03 |
| 6 | 胡晨曦 | 长城国瑞证券 | 医药生物 | 69.32% | 77.42% | 45.47% | 12.50% | 7 | -27.10% | 2025-07-08 |
| 7 | 阳景 | 浦银国际证券 | 医药生物 | 69.08% | 63.15% | 34.03% | 100.00% | 3 | 0.00% | 2025-07-30 |
| 8 | 阳景 | 浦银国际证券 | 医药生物 | 69.05% | 38.31% | 31.60% | 100.00% | 4 | 0.00% | 2025-08-29 |
| 9 | 顾资然 | 中信证券 | 医药生物 | 69.04% | 66.43% | 54.57% | 66.67% | 6 | -1.79% | 2025-09-03 |
| 10 | 顾资然 | 中信证券 | 医药生物 | 69.03% | 65.98% | 55.71% | 66.67% | 6 | -1.79% | 2025-08-25 |
| 11 | 顾资然 | 中信证券 | 医药生物 | 68.71% | 56.43% | 55.60% | 66.67% | 6 | -1.79% | 2025-08-15 |
| 12 | 胡晨曦 | 长城国瑞证券 | 医药生物 | 68.59% | 64.92% | 28.13% | 12.50% | 7 | -27.10% | 2025-06-30 |
| 13 | 胡晨曦 | 长城国瑞证券 | 医药生物 | 68.57% | 71.49% | 18.57% | 12.50% | 7 | -27.10% | 2025-07-02 |
| 14 | 阳景 | 浦银国际证券 | 医药生物 | 68.56% | 48.26% | 24.38% | 100.00% | 4 | 0.00% | 2025-10-10 |
| 15 | 刘浩 | 华创证券 | 医药生物 | 68.37% | 77.32% | 11.86% | 29.41% | 2 | -47.33% | 2025-07-11 |
| 16 | 唐寅灏 | 中信证券 | 医药生物 | 68.29% | 43.46% | 17.92% | 85.71% | 13 | -8.47% | 2025-09-30 |
| 17 | 胡晨曦 | 长城国瑞证券 | 医药生物 | 68.29% | 74.00% | 43.51% | 12.50% | 7 | -27.10% | 2025-07-07 |
| 18 | 顾资然 | 中信证券 | 医药生物 | 68.15% | 58.21% | 53.91% | 66.67% | 6 | -1.79% | 2025-08-22 |
| 19 | 刘浩 | 华创证券 | 医药生物 | 68.09% | 71.10% | 18.63% | 29.41% | 2 | -47.33% | 2025-07-04 |
| 20 | 胡晨曦 | 长城国瑞证券 | 医药生物 | 68.03% | 64.10% | 27.04% | 12.50% | 6 | -27.10% | 2025-06-18 |